2026 Market SizeUSD 688.3 MnBase year
2027 EstimateUSD 705.0 MnEstimated year
2036 ForecastUSD 875.2 MnForecast value
CAGR2.4%2027–2036
Largest RegionMiddle East & Africa2026
Malaria Diagnostics Market Overview
The global malaria diagnostics market was valued at USD 688.3 million in 2026 and is estimated at USD 705.0 million in 2027. Revenue is forecast to reach USD 875.2 million by 2036, representing a 2.4% CAGR during 2027–2036.
282 millionEstimated malaria cases worldwide in 2024WHO World Malaria Report 2025
610,000Estimated malaria deaths worldwide in 2024WHO World Malaria Report 2025
245 millionMalaria RDTs distributed by control programmes in 2020WHO
3BIOCREDIT malaria RDTs prequalified in April 2026WHO Prequalification
The market comprises malaria-specific rapid antigen tests, microscopy reagents and supplies, molecular detection assays and associated diagnostic equipment. It excludes antimalarial medicines, vaccines, insecticide-treated nets and general laboratory testing not attributable to malaria. Public procurement and donor-financed testing programmes shape sales in endemic settings, while hospitals and reference laboratories sustain microscopy and confirmatory testing.
WHO estimated 282 million malaria cases and 610,000 deaths in 2024, indicating a continuing requirement for prompt parasite-based diagnosis. Rapid diagnostic tests are especially important where trained microscopists and reliable laboratory infrastructure are unavailable. Testing demand is not equivalent to infection counts because fever triage, repeat testing and surveillance also consume diagnostics.
Procurement agencies prioritize WHO-prequalified tests with suitable sensitivity, storage stability and cost. The Global Fund publishes procurement price and quality data, and WHO recommends adapting test selection to local Plasmodium species. Parasites with pfhrp2 or pfhrp3 gene deletions can escape HRP2-only detection, encouraging more reliable alternatives that measure parasite lactate dehydrogenase.
In April 2026 WHO prequalified three BIOCREDIT malaria rapid diagnostic tests, extending access to pLDH-based alternatives. Premier Medical introduced additional dual- and triple-antigen First Response assays during 2025 and 2026. These developments support product replacement and better diagnostic coverage, but budget constraints and tender-based pricing limit average revenue growth considerably in competitive tenders.
Source: WHO World Malaria Report 2025; WHO diagnostic testing; Global Fund procurement reporting; WHO prequalification announcement.
Key Takeaways: Malaria Diagnostics Market
- Base-year market size: The malaria diagnostics market represented USD 688.3 million in 2026.
- Forecast and CAGR: The market is estimated at USD 705.0 million in 2027 and forecast at USD 875.2 million in 2036, a 2.4% CAGR.
- Leading type: Rapid diagnostic tests represented an estimated ~63% of 2026 revenue, reflecting broad field deployment.
- Leading application: Initial fever screening represented an estimated ~58% of 2026 revenue, supported by community case management.
- Largest region: Middle East & Africa represented an estimated ~48% of 2026 revenue, reflecting the concentration of malaria burden in sub-Saharan Africa.
- Growth drivers: Public procurement, WHO prequalification and new pLDH-based assays sustain diagnostic demand.
- Competitive landscape: Abbott, Access Bio, Premier Medical, Rapigen, SD Biosensor and Meril have documented malaria-testing activity.
- Report coverage: The study evaluates four segmentation dimensions, five regions, leading suppliers and the 2027–2036 outlook.
Report Scope & Market Segmentation
This study measures manufacturer revenue attributable to malaria-specific diagnostic tests, reagents and directly related systems, across routine case management, surveillance and confirmatory laboratory workflows.
| Report Attribute | Coverage |
|---|
| Base Year | 2026 |
| Estimated Year | 2027 |
| Forecast Period | 2027–2036 |
| Market Measurement | Revenue, USD million/billion |
| By Type | Rapid Diagnostic Tests; Microscopy; Molecular Diagnostics; Other Diagnostics |
| By Application | Initial Fever Screening; Confirmatory Diagnosis; Surveillance and Elimination; Treatment Monitoring |
| By End User | Public Health Programmes; Hospitals and Clinics; Diagnostic Laboratories; Community Health Providers |
| By Detection Target | HRP2 Antigen; pLDH Antigen; Microscopy-Based Parasite Identification; Nucleic Acid Targets |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; United Kingdom; India; Indonesia; China; Brazil; Nigeria; Democratic Republic of the Congo; Uganda |
| Key Market Players | Abbott Laboratories; Access Bio, Inc.; Premier Medical Corporation Pvt. Ltd.; SD Biosensor; Rapigen Inc.; Meril Diagnostics Pvt. Ltd. |
Market Definition & Revenue Boundaries
Included products are malaria-specific lateral-flow antigen tests, microscopy stains and supplies, nucleic-acid amplification assays and dedicated instruments where the revenue is attributable to malaria testing. Diagnostic revenue is recognized at the manufacturer or supplier level rather than counting the entire cost of a clinical consultation or antimalarial treatment. Multiplex panels are apportioned to the malaria diagnostic component to avoid double-counting revenue from other pathogens.
The type dimension separates rapid tests, microscopy, molecular assays and other diagnostic technologies. Application identifies the clinical or surveillance purpose, while end user describes the purchasing or testing setting. Detection target distinguishes antigen and parasite-identification mechanisms; these are independent views of the same market, not additive revenue streams.
Malaria Diagnostics Market Dynamics
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2027–2029 | 2030–2032 | 2033–2036 |
|---|
| Persistent malaria burden and fever triage demand | High | +2.00% | High | High | High |
| Public procurement and diagnostic access programmes | High | +1.50% | High | Medium | Medium |
| pLDH-based assay adoption in deletion-prone settings | Medium | +1.10% | Medium | High | High |
| Microscopy and molecular quality improvements | Medium | +0.80% | Medium | Medium | High |
| Local manufacturing and expanded distribution | Low | +0.60% | Medium | Medium | Medium |
| Others (surveillance, elimination and training) | Low | +0.40% | Medium | Medium | Medium |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2027–2029 | 2030–2032 | 2033–2036 |
|---|
| Tender-based price pressure on rapid tests | High | -1.60% | High | High | High |
| International funding volatility and aid reductions | High | -1.00% | High | Medium | Medium |
| Infrastructure and skilled workforce constraints | Medium | -0.80% | Medium | Medium | Medium |
| Others (stockouts, seasonality and quality failures) | Low | -0.60% | Medium | Medium | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 2.4% CAGR for 2027–2036; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
High disease burden sustains broad testing demand
WHO estimated 282 million malaria cases in 2024 and 610,000 deaths, illustrating the persistent public-health burden. Each suspected case requires a prompt diagnostic decision, but the number of tests exceeds confirmed infections because many febrile illnesses are not malaria. In endemic districts, community health workers use antigen tests where microscopy infrastructure is limited. Government and donor purchasing therefore remains a core volume driver, although it is sensitive to funding cycles, stock management and local disease incidence. Stronger surveillance can also increase testing even when malaria transmission declines.
Diagnostic quality standards favor validated suppliers
WHO advises using prequalified malaria rapid diagnostic tests for procurement and selecting products according to local parasite species, target antigens, shelf life and thermal stability. This raises the value of independently evaluated performance and manufacturing quality systems. Public buyers may favor products with demonstrated accuracy at low parasite density, particularly for rural deployment. However, tender competition and strict procurement pricing constrain revenue per test. Suppliers able to maintain stable production, deliver consistent lots and support training can compete for larger multi-country contracts despite modest headline market growth.
Antigen deletions accelerate test redesign
Parasites lacking pfhrp2 or pfhrp3 genes may evade diagnostic assays based solely on HRP2, creating a serious false-negative risk. WHO has issued surveillance protocols and recommends shifting diagnostic strategies when these deletions compromise test performance. Newer combinations targeting pLDH as well as HRP2 can help address local gaps, although field performance must be independently assessed. WHO prequalified three BIOCREDIT malaria tests in April 2026, expanding the pool of alternatives. Replacement of older tests generates product-mix opportunities even without a proportionate rise in total test volume.
Funding and distribution disruptions restrain access
The malaria diagnostics business depends on reliable public-health budgets, donor commitments and procurement logistics. Disruptions to international assistance can interrupt testing supplies, particularly in rural areas that lack alternative distributors. Reuters reported in June 2025 that Nigeria was developing domestic production capacity to reduce dependence on imports following aid cuts. Local manufacturing may improve availability, but it can also intensify price competition. Inventory planning is difficult because outbreaks, seasonal transmission and changing treatment protocols cause demand to fluctuate sharply between districts and procurement cycles.
Microscopy and molecular assays retain specialized roles
WHO guidance continues to identify microscopy and rapid antigen tests as the principal routine methods for parasitological confirmation. Microscopy supports parasite identification, density measurement and investigation of treatment failure, but it depends on trained personnel and quality assurance. Molecular assays are valuable in surveillance, low-density infection studies and specialized laboratories, yet their cost and infrastructure needs limit routine use in many endemic communities. Consequently, the market combines high-volume inexpensive field tests with smaller specialized laboratory categories, and suppliers must tailor their offerings to distinct clinical workflows.
Sources: WHO World Malaria Report 2025; WHO malaria guidelines; WHO prequalification; Global Fund procurement; Reuters.
Market Trends & Growth Opportunities
pLDH targets gain relevance in affected regions
Malaria diagnostic manufacturers are expanding beyond HRP2-only formats as parasite gene deletions create false-negative risks. WHO recommends alternative antigen targets in settings where deletion prevalence materially compromises HRP2 testing. The April 2026 prequalification of three BIOCREDIT assays illustrates the move toward pLDH-based detection. Procurement decisions increasingly consider the local distribution of parasite species and gene deletions rather than selecting a universal test. The trend supports targeted product replacement, updated training and additional validation requirements, while the market remains highly sensitive to public-sector purchasing prices.
Multi-antigen rapid tests address species differentiation
Manufacturers are combining HRP2 and pLDH targets to improve differentiation of Plasmodium falciparum and Plasmodium vivax infections. Abbott markets Bioline assays with species-oriented antigen combinations, while Premier Medical announced new dual- and triple-antigen formats in 2025 and March 2026. These designs may improve diagnostic utility in mixed-transmission regions, although laboratory validation and field conditions determine actual performance. Procurement teams must balance antigen coverage, shelf life and price per test. As a result, product differentiation increasingly rests on clinically relevant detection coverage rather than simply shorter test times.
Domestic manufacturing diversifies supply chains
Countries with substantial malaria burden are exploring domestic production to protect diagnostic supply against external funding and logistics disruptions. In June 2025 Reuters reported plans for a Nigerian facility developed with SD Biosensor to manufacture rapid HIV and malaria tests. Such investments can shorten distribution routes and support procurement continuity, especially when demand surges during outbreaks. They also create new competitive pressure for importers and established international suppliers. Manufacturing scale alone does not guarantee market access because regulatory approvals, quality assurance, stable financing and government procurement decisions remain essential.
Quality assurance becomes central to procurement
WHO prequalification and lot-testing guidance encourage buyers to examine performance, storage stability and manufacturer quality systems before ordering malaria rapid tests. The Global Fund makes procurement transaction information available through its price and quality reporting platform, supporting transparent purchasing decisions. Suppliers are responding by emphasizing documented product performance and reliable supply. In high-temperature settings, thermal stability can be as important as laboratory sensitivity. These requirements may favor manufacturers with validated products and dependable quality management, although competitive tenders still restrict the prices they can command.
Laboratory testing complements decentralized screening
Point-of-care antigen tests dominate routine field workflows, while microscopy and molecular methods remain important in referral laboratories and surveillance. WHO identifies microscopy as valuable for parasite density and species identification, especially when treatment failure is suspected. Molecular testing can detect low-density infections for specialized surveillance, but equipment, reagent and training requirements limit universal adoption. Diagnostic programmes therefore increasingly use layered pathways, beginning with accessible field screening and escalating selected cases for confirmatory work. This approach creates demand for complementary products rather than replacing rapid tests outright.
Malaria Diagnostics Market Segmentation by Type
Report SegmentationBy Type
Malaria diagnostic revenue is divided into rapid diagnostic tests, microscopy, molecular diagnostics and other specialized methods. Product economics vary between low-cost decentralized antigen tests and higher-resource laboratory methods.
Leading TypeRapid Diagnostic Tests
Rapid diagnostic tests represented an estimated ~63% of 2026 revenue. Their appeal is strongest in community settings where microscopy services are unavailable and a rapid treatment decision is essential. WHO recommends parasite-based diagnosis for suspected malaria, and prequalified antigen tests allow trained frontline workers to deliver results without complex equipment. Public tenders account for much of this volume, making prices competitive. HRP2 and pLDH test combinations are increasingly relevant where antigen deletion patterns complicate case detection.
Laboratory ReferenceMicroscopy
Microscopy remains central to laboratory confirmation, parasite species identification and parasite density measurement. Trained microscopists can examine thick and thin blood films and support investigations of suspected treatment failure. The method requires staining materials, instruments, training and ongoing quality assurance, which limits its availability at isolated clinics. Microscopy retains a durable role in hospitals and reference laboratories even as rapid antigen testing dominates routine field screening. Procurement includes reagents and consumables rather than only microscope equipment.
Specialized GrowthMolecular Diagnostics
Molecular diagnostics can detect low-density parasite infections and support epidemiological research or elimination surveillance. PCR and related methods require laboratory equipment, reagents and trained operators, so they are not the default clinical pathway in most high-burden communities. As elimination programmes seek to identify asymptomatic or residual infections, molecular testing may grow faster from a smaller base. Its use complements microscopy and antigen screening rather than replacing the rapid tests that enable frontline case management.
Future technology mix will depend on public procurement budgets, WHO product guidance and regional parasite genetics. Broad RDT access should remain the core commercial volume driver.
Malaria Diagnostics Market Segmentation by Application
Report SegmentationBy Application
Applications include initial fever screening, confirmatory diagnosis, surveillance and elimination, and treatment monitoring. These use cases have different sensitivity requirements and purchasing channels.
Leading ApplicationInitial Fever Screening
Initial fever screening represented an estimated ~58% of 2026 revenue. Many patients presenting with fever do not have malaria, so rapid confirmation helps avoid inappropriate antimalarial prescribing and directs attention to other illnesses. Community programmes rely heavily on antigen tests, especially in rural settings with limited microscopy access. Seasonal outbreaks can increase test volumes sharply, while prevention successes may reduce confirmed cases without eliminating the need for testing. Programmes therefore plan supplies against suspected fever episodes rather than confirmed malaria cases alone.
Clinical VerificationConfirmatory Diagnosis
Confirmatory diagnosis supports difficult cases, discordant rapid-test findings and suspected severe disease. Hospitals and laboratories use microscopy for parasite identification and density assessment, while molecular methods are applied selectively when enhanced sensitivity is required. WHO guidance emphasizes prompt parasitological confirmation but recognizes that emergency treatment decisions may need to proceed before results in severe cases. This segment depends on laboratory capability, trained staff and quality control, producing a distinct spending profile from community rapid screening.
Elimination PrioritySurveillance and Elimination
Surveillance and elimination programmes seek to identify residual transmission and track diagnostic vulnerabilities, including pfhrp2 and pfhrp3 deletions. These programmes may deploy targeted antigen tests, microscopy and molecular assays to characterize infections and guide interventions. Demand can increase as case numbers decline because detecting low-density and geographically scattered infections becomes operationally more complex. However, spending is sensitive to national elimination budgets and donor support, and specialized testing often remains concentrated in reference laboratories.
Application shares reflect modeled 2026 revenue allocations, not published transaction-level statistics. Clinical and surveillance requirements increasingly shape the selection of antigen targets.
Malaria Diagnostics Market Segmentation by End User
Report SegmentationBy End User
Malaria tests are purchased and used through public health programmes, hospitals and clinics, diagnostic laboratories and community health providers. Procurement and actual test administration may occur in different institutions.
Largest PurchaserPublic Health Programmes
Public health programmes coordinate malaria case management and surveillance in endemic countries. Central tenders and donor-supported procurement favor standardized, quality-assured tests that can be distributed to numerous facilities. The Global Fund reports procurement prices and supplier information, helping buyers compare products and track costs. Government purchasing is exposed to fiscal cycles, programme priorities and logistics disruptions, so manufacturers compete on dependable delivery as well as unit price. These programmes remain the principal route for large-scale rapid-test distribution.
Clinical CareHospitals and Clinics
Hospitals and clinics use malaria tests to assess febrile patients, confirm suspected infections and manage severe disease. Larger facilities may combine rapid tests with microscopy, allowing more detailed parasite assessment and review of discordant results. Demand is influenced by local transmission, referral patterns and laboratory staffing. Urban hospitals also evaluate imported malaria in travelers, but this is a smaller commercial use case than endemic-area diagnosis. Procurement may be managed by hospitals directly or supplied through public health systems.
Specialist TestingDiagnostic Laboratories
Diagnostic laboratories provide microscopy quality assurance, molecular testing and reference confirmation for malaria programmes. They support surveillance studies, assay validation and investigation of difficult infections. Revenue per test can be higher for molecular methods, but volumes are smaller than decentralized rapid screening. Investment depends on laboratory networks, staff training and available equipment. Partnerships with public health authorities help laboratories support national diagnostic standards and investigate changes in parasite antigen expression.
Community health providers extend access to underserved populations, often using tests purchased centrally rather than through independent commercial channels.
Malaria Diagnostics Market Segmentation by Detection Target
Report SegmentationBy Detection Target
The detection-target view separates HRP2 antigen, pLDH antigen, microscopy-based parasite identification and nucleic-acid targets. This is a technology classification of the same market revenue.
Established AntigenHRP2 Antigen
HRP2 has historically been a common target for detecting Plasmodium falciparum infection because suitable rapid tests can provide strong diagnostic performance. However, parasites lacking pfhrp2 or pfhrp3 genes may yield false-negative HRP2 results. WHO has published protocols for monitoring these deletions and recommends alternative diagnostic strategies where they materially affect case detection. Buyers must consider local deletion prevalence and quality assurance rather than relying solely on historic test familiarity. HRP2 remains important but faces growing pressure in affected geographies.
Alternative TargetpLDH Antigen
Parasite lactate dehydrogenase offers an alternative target for rapid diagnosis, including tests designed to distinguish falciparum and vivax malaria. Abbott and Premier Medical market combinations incorporating pLDH, and WHO prequalified three BIOCREDIT products in April 2026. Target selection must match local parasite species, deletion patterns and validated test performance. pLDH adoption creates replacement opportunities for suppliers with reliable assays, but product cost, sensitivity and field conditions still determine procurement outcomes.
Reference MethodsMicroscopy and Nucleic Acids
Microscopy identifies parasites visually and can quantify parasite density, while nucleic-acid assays detect parasite genetic material. These approaches are valuable for reference confirmation, surveillance and low-density infection investigations. Both require more laboratory resources than a typical lateral-flow antigen test. They serve complementary clinical and public-health needs and should not be conflated with antigen-target categories when allocating revenues. Diagnostic programmes select them according to case complexity, available expertise and surveillance objectives.
All detection-target shares must be reconciled within the same 2026 revenue base and should not be added to the independent type, application or end-user totals.
Malaria Diagnostics Market Regional Analysis
Malaria diagnostic spending is concentrated in endemic areas, but supplier revenue also reflects manufacturing, surveillance and imported-case testing in non-endemic countries. Middle East & Africa is the largest modeled region, while Asia-Pacific and Latin America require species-sensitive product portfolios.
North America
Specialized market - Imported cases and reference testingNorth America is a comparatively small market for malaria diagnostics because sustained indigenous transmission is uncommon across most of the region. Demand is concentrated in travel medicine, hospital laboratories, reference confirmation and public-health surveillance. Rapid antigen tests provide an initial aid to diagnosis, but microscopy remains essential for species identification and assessment of parasite density. Abbott markets the BinaxNOW Malaria test for use in symptomatic patients, illustrating the importance of specialized hospital-oriented products. Molecular testing is used selectively for difficult cases and surveillance rather than broad community screening. U.S. clinicians must consider malaria in travelers returning from endemic countries, where delays in diagnosis can have severe consequences. Purchasers emphasize reliable test performance, laboratory workflow compatibility and access to confirmatory expertise rather than the lowest unit cost alone. The region also contributes research and regulatory capabilities relevant to product development globally. Its share of worldwide malaria testing revenue is therefore smaller than the burden-heavy endemic regions, although its average spending per complex case can be higher. Future growth is likely to depend on travel patterns, reference laboratory investment and improvements in detecting low-density infections.
Priority country signals
United States
Selected market signalImported malaria is evaluated through clinical laboratories and public-health reference systems. Rapid tests can help clinicians triage suspected infections, but blood-smear microscopy is needed for parasite identification and quantification. Product demand is tied to travel exposure and diagnostic readiness rather than mass community screening. Laboratories also maintain emergency protocols and trained staff to avoid delays when an imported case requires urgent treatment.
Source: Abbott.
Europe
Reference laboratory market - Travel medicine and surveillanceEuropean malaria diagnostic demand is driven principally by imported infections, specialist clinical services and reference laboratory testing. Hospitals need rapid access to microscopy and, where appropriate, antigen testing for febrile travelers returning from endemic destinations. Molecular assays may be used in specialist centres for confirmatory identification or research, although they do not displace microscopy in urgent clinical management. European suppliers also participate in international diagnostic distribution and product development, so the region has commercial importance beyond its domestic malaria burden. Procurement typically emphasizes regulatory compliance, laboratory quality systems and diagnostic accuracy rather than the very high volumes characteristic of endemic-country public programmes. Seasonal travel patterns can influence testing needs, but overall demand is more stable and smaller than in sub-Saharan Africa. Clinical pathways rely on awareness of travel history and timely parasitological testing. Laboratories require trained staff and dependable access to reagents for thin and thick blood films. The region may benefit from more sensitive molecular methods and digital microscopy, but cost-effectiveness and workflow validation remain central. European sales are expected to grow modestly as international travel and specialized testing continue.
Priority country signals
United Kingdom
Selected market signalHospitals and specialist laboratories assess imported malaria among returning travelers. Testing pathways emphasize prompt microscopy, appropriate use of rapid antigen assays and referral expertise. Demand is therefore linked to travel medicine, laboratory readiness and diagnostic quality rather than routine population screening. Specialist referral networks help clinicians interpret unusual findings and support surveillance of infections acquired abroad.
Source: WHO malaria guidelines.
Asia-Pacific
Mixed-species testing - Pf and Pv differentiationAsia-Pacific contains both malaria-endemic countries and large territories approaching elimination, producing varied diagnostic needs. In countries with Plasmodium vivax as well as falciparum transmission, test selection must support appropriate species differentiation. WHO guidance highlights the relevance of antigen combinations targeting pLDH when vivax infection is common or HRP2-only tests are unsuitable. National programmes use rapid tests in remote health posts while retaining microscopy in hospitals and surveillance laboratories. Elimination-oriented programmes may require more sensitive testing for residual or low-density infections, creating demand for molecular methods in selected settings. Public procurement budgets and national control strategies remain central to product volumes. Supply-chain resilience matters because mountainous, island and rural communities may be difficult to reach. The region also hosts diagnostic manufacturing capacity and export-oriented suppliers, including Indian manufacturers serving international programmes. Product competition is shaped by regulatory standards, tender prices and ability to meet local parasite patterns. Although malaria burden has declined in parts of the region, surveillance and border-area testing remain essential. Over the forecast period, spending may shift from high-volume routine diagnosis toward targeted elimination and quality assurance in countries nearing transmission interruption.
Priority country signals
India
Selected market signalIndia combines malaria control and elimination objectives with domestic diagnostic manufacturing. Programmes require affordable field tests and microscopy support, while Plasmodium vivax detection is important in relevant transmission areas. Premier Medical produces malaria antigen test formats in India for domestic and export markets. Procurement programmes also require appropriate storage conditions, dependable supply and quality assurance for tests deployed across varied climates.
Source: Premier Medical.
Indonesia
Selected market signalIsland geography and heterogeneous malaria transmission require decentralized testing capacity. Rapid diagnostic tests support remote case management, while laboratory microscopy and surveillance help identify parasite species and track progress toward elimination. Training, distribution planning and consistent access to consumables are necessary to maintain testing across distant island communities and high-risk border districts.
Source: WHO diagnostic testing.
Latin America
Elimination surveillance - Remote-area accessLatin American demand for malaria diagnostics is concentrated in endemic zones, forest communities and border areas where timely access to testing can be difficult. Rapid antigen tests are valuable for outreach and decentralized case management, while microscopy remains important for species identification and treatment monitoring. Plasmodium vivax plays a significant role in parts of the region, making the choice of diagnostic target particularly relevant. Public programmes must maintain supplies in geographically dispersed settings where transport delays and seasonal changes complicate stock planning. Elimination strategies increasingly require sensitive surveillance to identify residual transmission, especially when overall case numbers decline. Specialized molecular methods can support investigations and reference testing, but routine access depends on laboratory infrastructure and funding. Procurement is influenced by national health budgets, donor partnerships and cross-border coordination. Manufacturers must balance affordable field tests with quality assurance and storage conditions suited to tropical climates. The region represents a smaller share of global value than sub-Saharan Africa, but offers opportunities in differentiated antigen assays and surveillance tools. Growth is likely to be gradual as programmes shift from broad case management toward targeted testing and sustained elimination monitoring.
Priority country signals
Brazil
Selected market signalMalaria diagnosis is particularly relevant in Amazonian transmission areas, where distance from laboratories can delay care. Rapid tests and microscopy are complementary, with surveillance programmes supporting identification of residual infections and local transmission patterns. Testing access also depends on transport networks, trained personnel and sustained public funding in geographically isolated communities, particularly during seasonal transmission peaks.
Source: WHO malaria report.
Middle East & Africa
Largest region - ~48% of 2026 revenueMiddle East & Africa represented an estimated ~48% of 2026 revenue, reflecting the high concentration of malaria cases in sub-Saharan Africa and the scale of donor-supported diagnostic programmes. Community health workers, public clinics and hospitals rely on rapid antigen tests to confirm suspected malaria before treatment, particularly where microscopy services are unavailable. WHO estimated 282 million malaria cases worldwide in 2024, with Africa carrying the overwhelming majority of the burden. Procurement volumes depend on government budgets, international financing, tender schedules and reliable delivery to remote health facilities. Funding disruptions can produce stockouts even when clinical demand remains substantial. WHO guidance on pfhrp2 and pfhrp3 deletions is particularly important in affected countries, encouraging validated alternative antigen targets and more nuanced procurement. Domestic production initiatives are also emerging: Reuters reported in June 2025 on a Nigerian manufacturing project involving SD Biosensor. The region remains the largest modeled commercial opportunity, but competitive tender pricing and budget constraints restrain revenue growth relative to underlying testing needs. Over 2027–2036, quality-assured supply, improved surveillance and antigen innovation should shape demand more strongly than price increases.
Priority country signals
Nigeria
Selected market signalNigeria carries a substantial share of global malaria burden and relies on broad community diagnostic access. In June 2025 Reuters reported plans for domestic malaria test production with SD Biosensor involvement, reflecting efforts to strengthen supply security amid aid uncertainty. Local manufacturing can potentially reduce import dependence, but procurement contracts, regulatory review and quality management remain essential for reliable field deployment.
Source: Reuters.
Democratic Republic of the Congo
Selected market signalHigh malaria burden and geographically dispersed communities make reliable rapid-test distribution essential. Public procurement and partner-supported programmes must maintain quality-assured supplies while supporting microscopy and surveillance in referral laboratories. Community health workers require training and consistent test availability, while public programmes must coordinate logistics across remote districts with variable transmission intensity and seasonal outbreaks.
Source: WHO malaria report.
Competitive Landscape
Competition in malaria diagnostics spans high-volume antigen-test manufacturers, international point-of-care brands and laboratory technology suppliers. Procurement eligibility, antigen coverage, manufacturing consistency and price matter more than consumer brand recognition.
Global Point-of-Care SupplierAbbott Laboratories
Abbott markets Bioline malaria antigen assays that differentiate Plasmodium falciparum and vivax, as well as BinaxNOW Malaria for selected clinical markets. Its broad point-of-care distribution capabilities and published product specifications support access to both endemic-country and specialized hospital testing channels.
Rapid Test SpecialistAccess Bio
Access Bio markets the CareStart malaria rapid diagnostic test portfolio. Its specialization in low-complexity in vitro diagnostics aligns with community testing and procurement programmes that require compact test kits, quality documentation and dependable field distribution.
Indian Manufacturing BasePremier Medical Corporation
Premier Medical markets First Response malaria antigen products and introduced additional HRP2/pLDH combinations during 2025–2026. Its product range includes tests designed for falciparum and vivax differentiation, supporting competition in public tenders and export markets.
Alternative Antigen DevelopmentRapigen and SD Biosensor
WHO prequalified three Rapigen BIOCREDIT pLDH-oriented malaria tests in April 2026. SD Biosensor is linked to a Nigerian local-manufacturing initiative reported in June 2025, reflecting an emerging supply-chain strategy for high-burden markets.
Competitive differentiation increasingly depends on validated performance against local parasite species and antigen-deletion patterns. WHO prequalification and procurement guidance provide buyers with a framework for comparing test quality, while public tender processes create sustained pricing pressure. Suppliers with stable production and distribution are better positioned to maintain programme contracts. Manufacturing quality assurance and post-market performance monitoring also influence procurement renewal decisions, especially where changing parasite genetics creates new testing requirements.
Manufacturers are also responding to supply-chain risks by developing local production partnerships and broader antigen combinations. Laboratory providers remain relevant for microscopy and molecular confirmation, but the greatest volume opportunity lies in reliable decentralized rapid testing. Companies without independently documented malaria-specific products should not be presented as confirmed market participants. In the forecast period, market access is likely to depend on product prequalification, evidence of reliable antigen detection and a supplier ability to serve remote clinics. Buyers also assess shelf life, temperature tolerance, package configuration and training needs. Local production initiatives may diversify supply, while established brands compete through documented quality and distribution networks.
Key Companies Profiled
- Abbott Laboratories
- Access Bio, Inc.
- Premier Medical Corporation Pvt. Ltd.
- SD Biosensor
- Rapigen Inc.
- Meril Diagnostics Pvt. Ltd.
Recent Developments in the Malaria Diagnostics Market
April 2026: WHO Prequalification listed three BIOCREDIT malaria rapid diagnostic tests targeting pLDH-based detection, strengthening the availability of quality-assured alternatives where HRP2 deletions threaten conventional testing. The listing provides public buyers with additional validated options for malaria programmes. WHO recommends monitoring parasite gene deletions and selecting antigen targets appropriate to local transmission patterns. Source
March 2026: Premier Medical announced a First Response malaria assay combining Pf HRP2, Pf pLDH and Pv pLDH detection, designed to support differentiation of falciparum and vivax infections in laboratory and point-of-care settings. The launch reflects continued investment in multi-target antigen formats that may improve diagnostic coverage in mixed-species settings. Procurement adoption will still depend on independent performance assessment, price and storage requirements. Source
December 2025: WHO published its World Malaria Report 2025, documenting the continuing global malaria burden and highlighting biological and financing threats to control programmes. The report estimated 282 million cases and 610,000 deaths in 2024. These findings reinforce the importance of sustained access to parasite-based diagnosis, particularly in high-burden communities and resource-constrained public health systems. Source
October 2025: UNOPS recorded a long-term procurement award for malaria rapid diagnostic tests, illustrating continued institutional purchasing of field diagnostic products for Southeast Asian programmes. The contract illustrates the role of centralized purchasing and quality assurance in maintaining test supplies. Country programmes must match procurement quantities to transmission patterns, storage requirements and frontline health-worker capacity. Source
September 2025: Premier Medical introduced a First Response falciparum HRP2/pLDH card test, adding a dual-antigen option for point-of-care malaria screening. The manufacturer positioned the product for use by trained healthcare professionals. Its combination of antigen targets reflects efforts to support diagnostic reliability where reliance on a single marker may be insufficient. Source
June 2025: Reuters reported plans for Nigerian manufacture of HIV and malaria test kits through a project involving SD Biosensor, intended to strengthen local access amid uncertainty in international assistance. The project was described as a way to reduce reliance on imports and increase supply resilience. Production capacity will need to be matched with regulatory compliance, public procurement demand and ongoing product quality assurance. Source
Market Outlook, 2027–2036
Malaria diagnostics revenue is forecast to increase from USD 705.0 million in 2027 to USD 875.2 million by 2036, representing a 2.4% CAGR during 2027–2036. Growth reflects continuing diagnostic access needs, offset by competitive procurement pricing.
| Forecast Variable | 2026–2027 Starting Point | Expected Effect Through 2036 |
|---|
| Disease burden | WHO estimated 282 million malaria cases in 2024 | Sustained field screening and surveillance demand |
| Public procurement | Large donor and government purchasing programmes | High test volumes with tender pricing pressure |
| Antigen evolution | Three BIOCREDIT tests prequalified April 2026 | Replacement of unsuitable HRP2-only assays |
| Local production | Nigeria diagnostic manufacturing initiative in 2025 | Potential supply resilience and competition |
| Laboratory capacity | Microscopy and molecular reference networks | Specialized testing growth from a smaller base |
| Funding exposure | International assistance uncertainty | Risk of stockouts and delayed purchasing |
Public-health programmes will remain the primary source of large malaria rapid-test orders, especially in sub-Saharan Africa. WHO guidance supports parasite-based diagnosis before treatment and favors quality-assured tests suitable for local epidemiology. Continued funding and distribution are essential because clinical need does not automatically translate into procurement revenue. As programmes strengthen coverage, test volumes can remain substantial even where prevention reduces confirmed infections. The principal uncertainty is whether public purchasing capacity keeps pace with operational needs.
Product innovation is expected to focus on alternative antigen targets and improved detection where pfhrp2 and pfhrp3 deletions compromise HRP2-only assays. New prequalified pLDH products may displace older formats, creating replacement demand rather than entirely new testing episodes. Manufacturers with validated performance, thermal stability and reliable lot quality should benefit. However, buyers are likely to resist higher prices unless additional diagnostic performance clearly addresses a local problem.
Microscopy and molecular methods will continue supporting clinical confirmation, species identification and elimination surveillance. Reference laboratories may expand targeted molecular testing for low-density infections, while routine rural diagnosis remains dominated by rapid antigen formats. Regional differences will be pronounced: endemic African markets emphasize decentralized volume, whereas Europe and North America focus on imported-case readiness and laboratory services. Asia-Pacific and Latin America combine routine case management with increasingly targeted elimination activities.
Competitive pressure is expected to persist as established international manufacturers and emerging local producers seek procurement contracts. Domestic manufacturing can improve access and reduce import reliance but must satisfy regulatory and quality requirements. The forecast assumes gradual market expansion rather than a sharp increase in average prices. Funding cuts, distribution failures and unrecognized antigen deletions present downside risks; stronger surveillance, improved product selection and dependable public purchasing could support performance above the baseline.
Report Coverage
The report examines malaria-specific diagnostic products, manufacturers, procurement dynamics, field deployment and reference testing across the 2027–2036 forecast horizon.
Market Sizing & Forecasting2026 market size, 2027 estimate, 2036 forecast and CAGR for 2027–2036.
Technology SegmentationRapid antigen tests, microscopy, molecular assays and other methods.
Application AnalysisInitial screening, confirmation, surveillance and treatment monitoring.
Regional & Country AnalysisFive regions and selected national malaria testing needs.
Competitive LandscapeDocumented suppliers, product development and procurement considerations.
Market DynamicsPublic financing, antigen deletions, quality standards and supply-chain risks.
Frequently Asked Questions
How large is the global malaria diagnostics market?
The market is modeled at USD 688.3 million in 2026, with USD 705.0 million estimated for 2027 and USD 875.2 million forecast for 2036. The figures represent malaria-specific diagnostic products and related supplies, excluding malaria treatment and prevention products.
What is the malaria diagnostics market CAGR?
The market is forecast to grow at 2.4% annually from 2027 to 2036, based on the publisher-endpoint-normalized revenue model. Public procurement, continued testing needs and new antigen formats support demand, while competitive tender pricing limits revenue expansion.
Which malaria diagnostic test type leads the market?
Rapid diagnostic tests represented an estimated ~63% of 2026 revenue. They support field screening without advanced laboratory infrastructure and are widely used by community health workers. Microscopy and molecular testing remain important for confirmation and surveillance.
Which region has the largest malaria diagnostics market?
Middle East & Africa represented an estimated ~48% of 2026 revenue, reflecting high malaria burden in sub-Saharan Africa and large public-health diagnostic programmes. The percentage is a modeled allocation rather than a directly reported transaction share.
What are the main malaria diagnostic methods?
Routine malaria diagnosis relies principally on antigen rapid diagnostic tests and blood-smear microscopy. Molecular methods, including PCR, are used selectively in reference laboratories and surveillance. Method selection depends on clinical urgency, available expertise and local parasite characteristics.
What is an HRP2 malaria rapid diagnostic test?
An HRP2 test detects a protein associated with Plasmodium falciparum infection. Some parasites have pfhrp2 or pfhrp3 gene deletions that can produce false-negative results, so WHO recommends monitoring local deletion patterns and considering alternative test targets where necessary.
Why are pLDH malaria tests gaining attention?
Parasite lactate dehydrogenase is an alternative antigen target that can support detection where HRP2-only testing is unreliable. WHO prequalified three BIOCREDIT malaria rapid diagnostic tests in April 2026, strengthening access to validated alternatives for affected settings.
Who are the key malaria diagnostics manufacturers?
Documented participants include Abbott Laboratories, Access Bio, Premier Medical Corporation, Rapigen, SD Biosensor and Meril Diagnostics. These organizations have product, prequalification, manufacturing or procurement evidence relevant to malaria diagnostics. The evidenced supplier set is deliberately narrower than the broader publisher company list because inclusion requires a traceable malaria-specific product or procurement record.
How does malaria diagnostic procurement work?
Governments and international partners purchase tests through public tenders and pooled procurement mechanisms. WHO prequalification, diagnostic performance, thermal stability, unit price and supply reliability are important selection criteria. The Global Fund publishes price and quality procurement information.
What are the challenges facing malaria diagnostic testing?
Challenges include funding uncertainty, remote distribution, laboratory staffing shortages, quality assurance and parasite antigen deletions that reduce some rapid-test sensitivity. Manufacturers and health programmes must coordinate procurement, training and surveillance to maintain reliable diagnosis. Test selection must reflect local parasite species and independently evaluated product performance.
Are molecular tests replacing malaria rapid diagnostic tests?
Molecular methods are useful for specialized surveillance and detecting low-density infections, but they generally require more laboratory infrastructure and expertise. Rapid antigen tests remain central to decentralized clinical screening, while microscopy continues to support parasite identification and density assessment.
What is the outlook for malaria diagnostics through 2036?
The market is forecast to reach USD 875.2 million in 2036. Continued diagnostic access, pLDH-based product replacement and stronger surveillance support gradual growth, while public funding pressures and tender competition remain major constraints. Product innovation is expected to focus on validated alternative antigens and dependable field supply.
Research Sources & Evidence Base
View research sources used for this overview
- WHO. World malaria report 2025, 2025-12-04.
- WHO. WHO guidelines for malaria, 2026-09-10.
- WHO. Malaria rapid diagnostic tests technical guidance, 2025.
- Global Fund. Price and Quality Reporting, undated.
- WHO. Diagnostic testing for malaria, undated.
- WHO Prequalification. Three malaria RDTs listed, 2026-04-14.
- WHO. Selecting and procuring malaria RDTs, undated.
- WHO. Surveillance template protocol for pfhrp2 pfhrp3 deletions, 2024-12-06.
- Abbott. Bioline Malaria Ag Pf Pv, undated.
- Abbott. BinaxNOW Malaria, undated.
- Access Bio. CareStart Malaria RDT product range, undated.
- Premier Medical. First Response Malaria Ag Pf Card Test, 2025-09-08.
- Premier Medical. First Response Pf Pv three-antigen test, 2026-03-10.
- UNOPS. Malaria RDT long-term procurement award, 2025-10-06.
- Reuters. Nigerian malaria test manufacturing expansion, 2025-06-19.